UA113174C2 - Стабільна ліофілізована композиція на основі fgf-18 - Google Patents

Стабільна ліофілізована композиція на основі fgf-18

Info

Publication number
UA113174C2
UA113174C2 UAA201314452A UAA201314452A UA113174C2 UA 113174 C2 UA113174 C2 UA 113174C2 UA A201314452 A UAA201314452 A UA A201314452A UA A201314452 A UAA201314452 A UA A201314452A UA 113174 C2 UA113174 C2 UA 113174C2
Authority
UA
Ukraine
Prior art keywords
fgf
stable lyophilized
lyophilized composition
composition
stable
Prior art date
Application number
UAA201314452A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113174(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA113174C2 publication Critical patent/UA113174C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід стосується стабільної ліофілізованої композиції, яка містить фактор росту фібробластів FGF-18, полоксамер 188 і цукрозу; способу одержання такої композиції; виробу, який містить вказану композицію і розчинник, які знаходяться в різних відсіках двокамерної системи.
UAA201314452A 2011-06-17 2012-06-15 Стабільна ліофілізована композиція на основі fgf-18 UA113174C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
PCT/EP2012/061495 WO2012172072A1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18

Publications (1)

Publication Number Publication Date
UA113174C2 true UA113174C2 (xx) 2016-12-26

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201314452A UA113174C2 (xx) 2011-06-17 2012-06-15 Стабільна ліофілізована композиція на основі fgf-18

Country Status (31)

Country Link
US (2) US9326944B2 (uk)
EP (2) EP2720710B1 (uk)
JP (1) JP5981538B2 (uk)
KR (1) KR102019520B1 (uk)
CN (2) CN103619347A (uk)
AR (1) AR086956A1 (uk)
AU (1) AU2012268987B2 (uk)
BR (1) BR112013032400B1 (uk)
CA (1) CA2836667C (uk)
CL (1) CL2013003618A1 (uk)
CO (1) CO6940377A2 (uk)
CY (1) CY1117933T1 (uk)
DK (1) DK2720710T3 (uk)
EA (1) EA024937B1 (uk)
EC (1) ECSP14013157A (uk)
ES (1) ES2575732T3 (uk)
HR (1) HRP20160566T1 (uk)
HU (1) HUE028355T2 (uk)
IL (1) IL229977A (uk)
MX (1) MX338017B (uk)
MY (1) MY170630A (uk)
PE (1) PE20141265A1 (uk)
PL (1) PL2720710T3 (uk)
PT (1) PT2720710E (uk)
RS (1) RS54875B1 (uk)
SG (1) SG195021A1 (uk)
SI (1) SI2720710T1 (uk)
TW (1) TWI527590B (uk)
UA (1) UA113174C2 (uk)
WO (1) WO2012172072A1 (uk)
ZA (1) ZA201308698B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
BR112016014717B1 (pt) 2013-12-24 2020-12-01 Ares Trading S.A. sistema de gelificação de dois componentes, método para produção de um hidrogel homogêneo, e artigo de produção
KR20180035911A (ko) * 2015-08-13 2018-04-06 메르크 파텐트 게엠베하 Fgf-18 화합물을 포함하는 조합 조성물
WO2019092637A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Extended release formulations for intra-articular applications
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DK1632574T3 (da) * 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
WO2000021548A2 (en) 1998-10-13 2000-04-20 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
CA2393200C (en) 1999-12-02 2011-07-12 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
AU2001286996A1 (en) 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
CA2500742C (en) 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
SI2586456T1 (sl) * 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
DK1962886T4 (da) * 2005-12-20 2022-05-02 Bristol Myers Squibb Co Stabile proteinformuleringer
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
US8207115B2 (en) 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN101663046B (zh) * 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
BRPI0809583B1 (pt) * 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
CA2708869C (en) * 2007-12-21 2016-06-28 F. Hoffmann-La Roche Ag Antibody formulation
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
DK2720710T3 (en) 2016-06-27
SI2720710T1 (sl) 2016-07-29
ZA201308698B (en) 2016-02-24
EP2720710A1 (en) 2014-04-23
ES2575732T3 (es) 2016-06-30
KR102019520B1 (ko) 2019-11-04
RS54875B1 (sr) 2016-10-31
BR112013032400A2 (pt) 2016-11-22
HRP20160566T1 (hr) 2016-06-17
IL229977A (en) 2017-01-31
TWI527590B (zh) 2016-04-01
EA201490032A1 (ru) 2014-05-30
US20160228374A1 (en) 2016-08-11
CN103619347A (zh) 2014-03-05
CA2836667A1 (en) 2012-12-20
CO6940377A2 (es) 2014-05-09
JP2014522807A (ja) 2014-09-08
AU2012268987B2 (en) 2016-09-08
EA024937B1 (ru) 2016-11-30
EP3056211A1 (en) 2016-08-17
ECSP14013157A (es) 2014-02-28
HUE028355T2 (en) 2016-12-28
NZ617992A (en) 2015-09-25
WO2012172072A1 (en) 2012-12-20
KR20140041600A (ko) 2014-04-04
JP5981538B2 (ja) 2016-08-31
MX2013014894A (es) 2014-09-01
MY170630A (en) 2019-08-21
TW201302217A (zh) 2013-01-16
CN107715104A (zh) 2018-02-23
US9326944B2 (en) 2016-05-03
CL2013003618A1 (es) 2014-07-04
CY1117933T1 (el) 2017-05-17
EP2720710B1 (en) 2016-03-23
AR086956A1 (es) 2014-02-05
PL2720710T3 (pl) 2016-09-30
PE20141265A1 (es) 2014-09-29
BR112013032400B1 (pt) 2021-07-20
SG195021A1 (en) 2013-12-30
MX338017B (es) 2016-03-29
CA2836667C (en) 2020-01-14
PT2720710E (pt) 2016-06-17
US20140121162A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
UA113174C2 (xx) Стабільна ліофілізована композиція на основі fgf-18
WO2016170348A3 (en) Sarna compositions and methods of use
PH12015501354A1 (en) Antiviral compounds
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
WO2012033813A3 (en) Compositions for dyeing keratin fibers
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
HK1205201A1 (en) Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections mrsa pbp2a mrsa
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
PL2825590T3 (pl) Lekkie wyroby, kompozycje zespolone oraz sposoby ich wytwarzania
PT2695623T (pt) Composições de vidros bioactivos, suas utilizações e respectivos métodos de preparação
SG195194A1 (en) Nanogels
WO2013021279A3 (en) Highly galactosylated antibodies
WO2014059424A3 (en) Flexible heat sealable decorative articles and method for making the same
DOP2013000250A (es) Composiciones de nucleasa terapeuticas y metodos
IN2015DN03322A (uk)
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
IN2014DN00161A (uk)
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
NZ706286A (en) Daptomycin formulations and uses thereof
BR112013027965A2 (pt) "composição de revestimento, substrato e método para revestir um substrato"
WO2013014677A8 (en) Matrix compositions for controlled release of peptide and polypeptide molecules